Your browser doesn't support javascript.
loading
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.
Henry, Edward; Al-Janabi, Hareth; Brouwer, Werner; Cullinan, John; Engel, Lidia; Griffin, Susan; Hulme, Claire; Kingkaew, Pritaporn; Lloyd, Andrew; Payakachat, Nalin; Pennington, Becky; Peña-Longobardo, Luz María; Prosser, Lisa A; Shah, Koonal; Ungar, Wendy J; Wilkinson, Thomas; Wittenberg, Eve.
Afiliación
  • Henry E; J.E. Cairnes School of Business & Economics, University of Galway, Galway, Ireland. e.henry4@universityofgalway.ie.
  • Al-Janabi H; Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Brouwer W; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. brouwer@eshpm.eur.nl.
  • Cullinan J; J.E. Cairnes School of Business & Economics, University of Galway, Galway, Ireland.
  • Engel L; Monash University Health Economics Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Griffin S; Centre for Health Economics, University of York, York, UK.
  • Hulme C; Institute of Health Research, University of Exeter Medical School, Exeter, UK.
  • Kingkaew P; Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
  • Lloyd A; Acaster Lloyd Consulting Ltd, London, UK.
  • Payakachat N; Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
  • Pennington B; School of Health and Related Research, University of Sheffield, Sheffield, UK.
  • Peña-Longobardo LM; Faculty of Law and Social Sciences, University of Castilla-La Mancha, Toledo, Spain.
  • Prosser LA; Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
  • Shah K; National Institute for Health and Care Excellence, London, UK.
  • Ungar WJ; The Hospital for Sick Children Research Institute/University of Toronto, Toronto, ON, Canada.
  • Wilkinson T; Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
  • Wittenberg E; Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Pharmacoeconomics ; 42(3): 343-362, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38041698
BACKGROUND: Omission of family and caregiver health spillovers from the economic evaluation of healthcare interventions remains common practice. When reported, a high degree of methodological inconsistency in incorporating spillovers has been observed. AIM: To promote emerging good practice, this paper from the Spillovers in Health Economic Evaluation and Research (SHEER) task force aims to provide guidance on the incorporation of family and caregiver health spillovers in cost-effectiveness and cost-utility analysis. SHEER also seeks to inform the basis for a spillover research agenda and future practice. METHODS: A modified nominal group technique was used to reach consensus on a set of recommendations, representative of the views of participating subject-matter experts. Through the structured discussions of the group, as well as on the basis of evidence identified during a review process, recommendations were proposed and voted upon, with voting being held over two rounds. RESULTS: This report describes 11 consensus recommendations for emerging good practice. SHEER advocates for the incorporation of health spillovers into analyses conducted from a healthcare/health payer perspective, and more generally inclusive perspectives such as a societal perspective. Where possible, spillovers related to displaced/foregone activities should be considered, as should the distributional consequences of inclusion. Time horizons ought to be sufficient to capture all relevant impacts. Currently, the collection of primary spillover data is preferred and clear justification should be provided when using secondary data. Transparency and consistency when reporting on the incorporation of health spillovers are crucial. In addition, given that the evidence base relating to health spillovers remains limited and requires much development, 12 avenues for future research are proposed. CONCLUSIONS: Consideration of health spillovers in economic evaluations has been called for by researchers and policymakers alike. Accordingly, it is hoped that the consensus recommendations of SHEER will motivate more widespread incorporation of health spillovers into analyses. The developing nature of spillover research necessitates that this guidance be viewed as an initial roadmap, rather than a strict checklist. Moreover, there is a need for balance between consistency in approach, where valuable in a decision making context, and variation in application, to reflect differing decision maker perspectives and to support innovation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidadores / Economía Médica Límite: Humans Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Nueva Zelanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidadores / Economía Médica Límite: Humans Idioma: En Revista: Pharmacoeconomics Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Nueva Zelanda